A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.

Sponsor
Yizhuo Zhang
Study ID
NCT06836492
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Pediatric Cancer
  • Rhabdomyosarcoma

Eligibility Criteria

Sex
ALL
Age
0 Years - 18 Years
Healthy Volunteers
Not accepted

Interventions

  • VAC，VAC/VII，CAV/IE — COMBINATION_PRODUCT
    Low risk: VAC Intermediate risk: VAC/VII High risk: CAV/IE Very high risk: CAV/VIP

Study Details

The purpose is to explore the efficacy and safety of the SYSUCC-RMS regimen for pediatric RMS patients and to explore the impact of concurrent radiotherapy and chemotherapy on the survival rate of low-risk, medium risk, high-risk, and extremely high-risk patients in children.

Key Dates

First listed
Feb 20, 2025
Start date
Jan 30, 2017
Status verified
Jan 2025
Primary completion
Sep 30, 2029
Completion
Dec 31, 2029

Study Design

Enrollment
300 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Low risk
  • Other: Moderate risk
  • Other: High risk
  • Other: Very high risk

Primary Outcome Measure

The objective response rate (ORR) [ Time Frame: Up to 1 year ]

Central Contacts

Related Studies